t
Renalytix PLC announced an amendment on 2 October 2026, clarifying that investment vehicles connected with Non-Executive Director Christopher Mills purchased 1,166,667 ordinary shares on 29 September 2026. These shares were acquired at £0.06 each on the London Stock Exchange, AIM, resulting in Christopher Mills and connected investment vehicles holding 18,201,690 Ordinary Shares, which represents 2.7% of the company's issued share capital.
| Date | 2 Oct 2026 |
| Time | 16:06:43 |
| Category | Director/PDMR dealings |
| ID | 4809X |
The following amendment has been made to the 'Director/PDMR Dealing' announcement released on 1 October 2026 at 16:06 under RNS No 2887X. The reference to ‘Nature of the transaction’ has been corrected to ‘Purchase of Ordinary Shares’. All other details remain unchanged. The full amended text is shown below.
Renalytix plc
(“Renalytix” or the “Company”)
Director/PDMR Dealing
LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills, Non-Executive Director, have completed the purchase of 1,166,667 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.06 per Ordinary Share.
Following completion of this purchase, Christopher Mills and the investment vehicles connected with him are interested in 18,201,690 Ordinary Shares representing 2.7% of the issued share capital of the Company, as enlarged by the recent equity placing.
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke (Corporate Finance) |
|
|
|
Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient’s risk with diabetic kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Harwood Capital LLP* |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Renalytix plc |
|||
|
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of £0.0025 each |
|||
|
|
|
||||
|
Identification code |
GB00BYWL4Y04
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£0.06 |
1,166,667 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
1,166,667 |
||||
|
|
|
||||
|
- Price |
£0.06 |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
29 September 2026 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
|||
*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher's shareholding is made up of ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP.